Venetoclax Plus Hypomethylating Agent for 7‐ Versus 14‐ Versus 21‐ Versus 28‐Day Cycles in Newly‐Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk–Stratified Analysis in 540 Patients

Sudhesh Kumar, Momna Warraich, Mahnoor Fatima, Kristen McCullough, Aref Al‐Kali, Hassan B. Alkhateeb, Kebede H. Begna, Abhishek A. Mangaonkar, Antoine N. Saliba, Mark R. Litzow, William Hogan, Mithun Shah, Mrinal M. Patnaik, Animesh Pardanani, Talha Badar, James Foran, Jeanne Palmer, Cecilia Arana Yi, Ayalew Tefferi, Naseema Gangat
American Journal of Hematology · Wiley · 2026-11-06 · DOI: 10.1002/ajh.70500

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles